Xenon Pauses Depression Trials After Safety Signal; Stock Slides Xenon paused new MDD and BPD enrollment after a psychiatry safety review; X-NOVA2 data expected Q1 2027. Credit: Xenon Pharmaceuticals Subscribe now Already have an account? Sign in.
